Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
2019 · New England Journal of Medicine · 2,755 citations
https://doi.org/10.1056/nejmoa1910231
K
Kenneth J. O’Byrne
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.2K
Papers
48.7K
Citations
91
h-index
371
i10-index
Kenneth J. O’Byrne is an academic researcher from Translational Research Institute. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 91, co-authored 997 publications.
ORCID: 0000-0002-6754-5633Papers by this author
worksImmune Checkpoint Inhibitors in Cancer Therapy
2022 · Current Oncology · 1,165 citations
https://doi.org/10.3390/curroncol29050247
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
2016 · The Lancet Oncology · 1,143 citations
https://doi.org/10.1016/s1470-2045(16)30033-x
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
2011 · The Lancet Oncology · 706 citations
https://doi.org/10.1016/s1470-2045(11)70149-8
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
2021 · Journal of Thoracic Oncology · 318 citations
https://doi.org/10.1016/j.jtho.2021.09.010
Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel
2019 · Microsystems & Nanoengineering · 197 citations
https://doi.org/10.1038/s41378-019-0045-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat